| Oct 30 2023 |
Telehealth Privacy and Security Risk Mitigation: Office for Civil Rights Provides Guidance to Providers, Patients |
Greenberg Traurig, LLP |
| Oct 30 2023 |
Lowest-Risk Clinical Trials Will Benefit from a New Notification Scheme and a Shorter Period for Application Processing |
McDermott Will & Emery |
| Oct 27 2023 |
AHLA Podcast: Anthony Burba Speaks on Clinical Decision Support Tools |
Barnes & Thornburg LLP |
| Oct 27 2023 |
Beltway Buzz, October 27, 2023 |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Oct 27 2023 |
SB 553 Workplace Violence Prevention: 12 Answers to Employers’ Frequently Asked Questions |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Oct 27 2023 |
McDermottPlus Check-Up: October 27, 2023 |
McDermott Will & Emery |
| Oct 27 2023 |
CMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation Program by November 13: Inflation Reduction Act Updates |
Epstein Becker & Green, P.C. |
| Oct 27 2023 |
HRSA Issues Notice Confirming 340B Registration Requirement |
McDermott Will & Emery |
| Oct 27 2023 |
Overcoming Safetyism & the Plaintiff Media Machine – Episode 66 [Video, Podcast] |
IMS Legal Strategies |
| Oct 27 2023 |
New York Adult Survivors Act Lookback Window Closes Soon |
Katz Banks Kumin LLP |
| Oct 27 2023 |
CCPA Amendments Extend Protections to Reproductive Health and Citizenship Status |
Sheppard, Mullin, Richter & Hampton LLP |
| Oct 27 2023 |
Trending in Telehealth: October 17 – 23, 2023 |
McDermott Will & Emery |
| Oct 27 2023 |
OIG To Pathology Lab: Don't Pay for Services you Don't Need |
McDermott Will & Emery |
| Oct 26 2023 |
HHS Office for Civil Rights Issues Resource for Providers to Educate Patients about Telehealth and Requirements Under HIPAA |
Barnes & Thornburg LLP |
| Oct 26 2023 |
Surge in Class Actions Under the Illinois Genetic Information Privacy Act |
von Briesen & Roper, s.c. |
| Oct 26 2023 |
FDA Issues New Warning Regarding Compounded Ketamine |
Foley & Lardner LLP |
| Oct 26 2023 |
A Name is Not Enough: Ninth Circuit Finds No Standing for First-to-File Shareholder to Appeal Securities Class Action |
Proskauer Rose LLP |
| Oct 26 2023 |
HHS-OIG Declines To Impose Sanctions On Physician Practice For Employed Physicians’ Bonus Compensation Structure Tied To ASC Facility Fee Profits |
Barnes & Thornburg LLP |
| Oct 25 2023 |
FCC Seeks Comment Regarding Role of Broadband Connectivity for Improving Maternal Health |
ArentFox Schiff LLP |
| Oct 25 2023 |
NM Talks Healthcare Podcast: Creating and Maintaining Privilege Over Internal Investigations [Podcast] |
Nelson Mullins |
| Oct 25 2023 |
DEA Further Extends Flexibilities for Controlled-Substance Prescribing Via Telemedicine |
McDermott Will & Emery |
| Oct 25 2023 |
Sanction Policies Can Help Drive Cybersecurity and HIPAA Compliance, OCR Says |
Jackson Lewis P.C. |
| Oct 24 2023 |
Digital Health 101: OCR Issues Resources to Educate Patients on Telehealth, PHI |
McDermott Will & Emery |
| Oct 24 2023 |
Policy Update to Foreign Residency Requirement for J-1 Exchange Visitors |
Greenberg Traurig, LLP |
| Oct 24 2023 |
Congress May Have a Vision for Psychedelic Regulation in the US |
Epstein Becker & Green, P.C. |
| Oct 24 2023 |
Dr. Jack of All Trades? OCR’s New Telehealth Guidance Suggests High Expectations on Providers |
Epstein Becker & Green, P.C. |
| Oct 24 2023 |
California Legislative Year-End Review: Preparing for 2024 (US) |
Squire Patton Boggs (US) LLP |
| Oct 24 2023 |
Stocking Naloxone in the Workplace: What Employers Need to Consider |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Oct 24 2023 |
Telehealth Update: DEA Extends Flexibility in Prescribing Controlled Substances via Telehealth Through 2024 |
Mintz |
| Oct 24 2023 |
OHCA’s Revised Regulations Following Comments from Industry Stakeholders |
Sheppard, Mullin, Richter & Hampton LLP |
| Oct 24 2023 |
FDA Updates Guidance Regarding Scientific Communications to HCPs about Unapproved Uses of Approved/Cleared Medical Devices and Drugs |
Nelson Mullins |
| Oct 24 2023 |
DEA Issues Second Temporary Extension of COVID-19 Telemedicine Prescribing Flexibilities, Through 2024 |
Epstein Becker & Green, P.C. |
| Oct 24 2023 |
DEA Further Extends COVID-19 Telemedicine Prescribing Flexibilities through December 31, 2024 |
Robinson & Cole LLP |
| Oct 24 2023 |
FDA Seeks to Increase Regulatory Oversight of Laboratory Developed Tests |
ArentFox Schiff LLP |
| Oct 24 2023 |
Lawsuit Alleges Panera’s Caffeinated Lemonade Caused Death |
Keller and Heckman LLP |
